To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic

Ann Rheum Dis. 2020 May;79(5):666-667. doi: 10.1136/annrheumdis-2020-217367. Epub 2020 Apr 2.

Authors

Francesca Romana Spinelli^#¹, Fulvia Ceccarelli^#², Manuela Di Franco², Fabrizio Conti²

Affiliations

¹ Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari-Reumatologia, Sapienza University of Rome, Roma, Lazio, Italy francescaromana.spinelli@uniroma1.it.
² Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari-Reumatologia, Sapienza University of Rome, Roma, Lazio, Italy.

^# Contributed equally.

PMID: 32241791
DOI: 10.1136/annrheumdis-2020-217367

No abstract available

Keywords: communicable diseases, imported; hydroxychloroquine; immune system diseases; social work.

Publication types

Letter
Comment

MeSH terms

Adenosine Monophosphate / analogs & derivatives
Alanine / analogs & derivatives
Antimalarials*
Betacoronavirus
COVID-19
Chloroquine
Coronavirus Infections
Coronavirus*
Pandemics
Pneumonia, Viral
SARS-CoV-2
Severe acute respiratory syndrome-related coronavirus*

Substances

Antimalarials
remdesivir
Adenosine Monophosphate
Chloroquine
Alanine